Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
5.85
-0.05 (-0.85%)
At close: Nov 5, 2026, 4:00 PM EST
5.76
-0.09 (-1.54%)
After-hours: Nov 5, 2026, 7:30 PM EST

Emergent BioSolutions Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-260.752.6-190.6-760.5-211.6219.5
Depreciation & Amortization
90.598.3112129.1130.6123.8
Other Amortization
7.69.87.421.34.14.1
Loss (Gain) From Sale of Assets
114.5-3.5-53.13.6-
Asset Writedown & Restructuring Costs
203.512.227.2524.919.441.7
Stock-Based Compensation
18.316.21823.145.142.4
Other Operating Activities
-7.9-0.6-0.5-20.8-23.233.7
Change in Accounts Receivable
56.825.5-24.4-21.6118.1-16.2
Change in Inventory
76.8-30.3-24.50.6-57.1-66.6
Change in Accounts Payable
8.4-8.4-3310.6-14-1.6
Change in Unearned Revenue
105.2-20.35.99.6-31.8
Change in Income Taxes
-1.9-1.723.3-16.228.7-31.3
Change in Other Net Operating Assets
-12.3-12.7167.6-49.6-87.42.5
Operating Cash Flow
200.1170.658.7-206.3-34.1320.2
Operating Cash Flow Growth
1439.23%190.63%----40.36%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-11.7-13.8-22.9-51.6-115.8-224.1
Sale of Property, Plant & Equipment
5.638.27.9---
Divestitures
--110.2270.2--
Sale (Purchase) of Intangibles
-47.95030-6.3-243.7-
Other Investing Activities
--5---21.8-
Investing Cash Flow
-5469.4125.2212.3-381.3-224.1

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
--28420598-
Long-Term Debt Repaid
--112.5-482.4-563.4-33.8-35.9
Total Debt Repaid
-324.1-112.5-482.4-563.4-33.8-35.9
Net Debt Issued (Repaid)
-178.6-112.5-198.4-543.4564.2-35.9
Issuance of Common Stock
2.72.210.810.2515.9
Repurchase of Common Stock
-31-26.3-1.2-2.5-88-119.8
Other Financing Activities
-11.5--1.2---1.2
Financing Cash Flow
-218.4-136.6-190-535.7481.2-141

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.1--1.20.5-0.3
Net Cash Flow
-72.3103.5-6.1-530.966.3-45.2

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
188.4156.835.8-257.9-149.996.1
Free Cash Flow Growth
13357.14%337.99%----75.67%
Free Cash Flow Margin
29.03%21.11%3.43%-24.58%-13.41%5.42%
Free Cash Flow Per Share
3.642.770.68-5.04-2.991.78
Levered Free Cash Flow
196.69207.8961.7-84.6-203.1339.19
Unlevered Free Cash Flow
217.46235.1598.68-50.96-183.9156.65

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
37.649.76468.33330.4
Cash Income Tax Paid
34.44026.552.86.271.6
Change in Working Capital
137.8-22.488.7-70.3-2.1-145
SEC Filings: 10-K · 10-Q